Please login to the form below
Farxiga
This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.
Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure
The heart failure market is becoming increasingly competitive, with Jardiance’s positive results in the EMPEROR-Reduced trial competing with AstraZeneca’s heart failure drug Farxiga, which scored an FDA
Latest news
-
AstraZeneca’s Forxiga approved in Japan for the treatment of CKD
Forxiga was approved as ‘Farxiga’ for the treatment of CKD in adults with and without type 2 diabetes in the US in April, after demonstrating results from a phase 3 study
-
AZ raises full-year guidance after completing Alexion acquisition in Q2
Farxiga. Meanwhile, Q2 net profit was down by 25% from the previous year, coming in at $550m for the quarter.
-
AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients
Also, of importance, we learned that [Farxiga]’s well-established safety profile was consistent in DARE-19,” he added. ... Initially, Farxiga was approved in 2014 to improve glycemic control in adults with type 2 diabetes when administered alongside
-
AZ forecasts growth in 2021 after revenues surge in Q4
That growth was led by an increase in revenue for AZ’s heart failure treatment Farxiga (dapagliflozin), which saw a 27% increase in 2020 to $1.96bn.
-
Bayer’s finerenone scores FDA priority review for chronic kidney disease
In September 202 0, AstraZeneca announced that its SGLT2 inhibitor Farxiga (dapagliflozin) plus standard of care reduced the risk of cardiovascular or renal death and worsening of renal function by 39% ... Earlier this year, Farxiga also won a priority
More from news
Approximately 14 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it secures approval for heart failure in both diabetic
-
China: AstraZeneca’s new engine for growth and innovation
One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
-
Transforming times at AstraZeneca
and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
